Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy
- 106 Downloads
Compliance with ethical standards
Conflict of interest
All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. No financial disclosures.
All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
- 5.Călugăru D, Călugăru M (2017) Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization. Eur J Ophthalmol 27(3):107–108Google Scholar
- 9.Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V (2015) Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocul Pharmacol Ther 31(6):357–362CrossRefPubMedGoogle Scholar